Europe - DUB:GL9 - IE0000669501 - Common Stock
The current stock price of GL9.I is 14.95 EUR. In the past month the price increased by 2.26%. In the past year, price increased by 2.75%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| BSN.DE | DANONE | 21 | 53.52B | ||
| BN.PA | DANONE | 21 | 53.52B | ||
| JDEP.AS | JDE PEET'S NV | 25.45 | 15.41B | ||
| JDE.DE | JDE PEET'S NV | 25.45 | 15.41B | ||
| KRZ.I | KERRY GROUP PLC-A | 16.29 | 12.75B | ||
| LOTB.BR | LOTUS BAKERIES | 38.19 | 6.16B | ||
| LOUP.PA | L.D.C. SA | 12.87 | 3.20B | ||
| SZU.DE | SUEDZUCKER AG | N/A | 1.95B | ||
| NWL.MI | NEWPRINCES SPA | 2.51 | 840.13M | ||
| SAVE.PA | SAVENCIA SA | 9.09 | 841.80M | ||
| FLOB.BR | FLORIDIENNE | 73.42 | 605.00M | ||
| BON.PA | BONDUELLE SCA | N/A | 291.71M |
Glanbia Plc engages in the manufacture and distribution of dairy and nutritional ingredients. The company is headquartered in Kilkenny, Kilkenny and currently employs 5,791 full-time employees. The Company’s segments include Glanbia Performance Nutrition and Glanbia Nutritionals. The Glanbia Performance Nutrition segment manufactures and sells sports nutrition and lifestyle nutrition products through a variety of channels, including specialty retail, online, Food, Drug, Mass, Club (FDMC), and gyms in a variety of formats, including powders, ready-to-eat (bars and snacking foods) and ready-to-drink beverages. The Glanbia Nutritionals segment manufactures and sells cheese, dairy and non-dairy nutritional and functional ingredients, and vitamin and mineral premixes targeting the increased market focus on health and nutrition. The Glanbia Nutritionals segment also includes the flavors business. The firm provides flavors and extracts to the food and beverage industries, with a focus on organic and natural ingredients. Its portfolio of brands includes Optimum Nutrition, Isopure, Nutramino, SlimFast, think!, and others.
GLANBIA PLC
Glanbia House, Ring Road
KILKENNY KILKENNY IE
Employees: 5791
Phone: 353567772200
Glanbia Plc engages in the manufacture and distribution of dairy and nutritional ingredients. The company is headquartered in Kilkenny, Kilkenny and currently employs 5,791 full-time employees. The Company’s segments include Glanbia Performance Nutrition and Glanbia Nutritionals. The Glanbia Performance Nutrition segment manufactures and sells sports nutrition and lifestyle nutrition products through a variety of channels, including specialty retail, online, Food, Drug, Mass, Club (FDMC), and gyms in a variety of formats, including powders, ready-to-eat (bars and snacking foods) and ready-to-drink beverages. The Glanbia Nutritionals segment manufactures and sells cheese, dairy and non-dairy nutritional and functional ingredients, and vitamin and mineral premixes targeting the increased market focus on health and nutrition. The Glanbia Nutritionals segment also includes the flavors business. The firm provides flavors and extracts to the food and beverage industries, with a focus on organic and natural ingredients. Its portfolio of brands includes Optimum Nutrition, Isopure, Nutramino, SlimFast, think!, and others.
The current stock price of GL9.I is 14.95 EUR. The price decreased by -1.19% in the last trading session.
GLANBIA PLC (GL9.I) has a dividend yield of 2.18%. The yearly dividend amount is currently 0.31.
GL9.I has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
14 analysts have analysed GL9.I and the average price target is 17.33 EUR. This implies a price increase of 15.95% is expected in the next year compared to the current price of 14.95.
GLANBIA PLC (GL9.I) operates in the Consumer Staples sector and the Food Products industry.
GLANBIA PLC (GL9.I) has a market capitalization of 3.64B EUR. This makes GL9.I a Mid Cap stock.
ChartMill assigns a technical rating of 8 / 10 to GL9.I. When comparing the yearly performance of all stocks, GL9.I turns out to be only a medium performer in the overall market: it outperformed 42.86% of all stocks.
ChartMill assigns a fundamental rating of 5 / 10 to GL9.I. GL9.I has an average financial health and profitability rating.
Over the last trailing twelve months GL9.I reported a non-GAAP Earnings per Share(EPS) of 1.16. The EPS decreased by -58.14% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 3.06% | ||
| ROA | 3.1% | ||
| ROE | 5.89% | ||
| Debt/Equity | 0.5 |
14 analysts have analysed GL9.I and the average price target is 17.33 EUR. This implies a price increase of 15.95% is expected in the next year compared to the current price of 14.95.
For the next year, analysts expect an EPS growth of -5.38% and a revenue growth 2.19% for GL9.I